Published in Oncotarget on October 13, 2015
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy. Clin Cancer Res (2016) 1.00
Targeting Stromal-Cancer Cell Crosstalk Networks in Ovarian Cancer Treatment. Biomolecules (2016) 0.80
Guidance of Signaling Activations by Cadherins and Integrins in Epithelial Ovarian Cancer Cells. Int J Mol Sci (2016) 0.78
Development of Phosphorothioate DNA and DNA Thioaptamers. Biomedicines (2017) 0.76
The Receptor Tyrosine Kinase AXL in Cancer Progression. Cancers (Basel) (2016) 0.75
Axl in ovarian cancer: a step forward for clinical breakthrough? Oncotarget (2016) 0.75
Protein S drives oral squamous cell carcinoma tumorigenicity through regulation of AXL. Oncotarget (2017) 0.75
Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res (2008) 8.17
Ovarian cancer development and metastasis. Am J Pathol (2010) 5.92
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Integrin signalling adaptors: not only figurants in the cancer story. Nat Rev Cancer (2010) 2.94
Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol (2013) 2.35
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Human cutaneous melanomas lacking MITF and melanocyte differentiation antigens express a functional Axl receptor kinase. J Invest Dermatol (2011) 2.09
Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res (1985) 2.06
Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer. J Natl Cancer Inst (2014) 1.93
Ovarian cancer spheroids use myosin-generated force to clear the mesothelium. Cancer Discov (2011) 1.88
Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol (2005) 1.62
Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. J Cell Biol (2012) 1.59
AXL is an essential factor and therapeutic target for metastatic ovarian cancer. Cancer Res (2010) 1.50
A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res (2013) 1.46
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med (2013) 1.38
Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET. Proc Natl Acad Sci U S A (2014) 1.34
Can tissue engineering concepts advance tumor biology research? Trends Biotechnol (2010) 1.32
The receptor tyrosine kinase Axl in cancer: biological functions and therapeutic implications. Int J Cancer (2013) 1.24
Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: growth features and cytogenetics. Int J Cancer (1993) 1.24
E-cadherin directly contributes to PI3K/AKT activation by engaging the PI3K-p85 regulatory subunit to adherens junctions of ovarian carcinoma cells. Oncogene (2009) 1.18
A framework for a personalized surgical approach to ovarian cancer. Nat Rev Clin Oncol (2015) 1.17
Activation of the FAK-src molecular scaffolds and p130Cas-JNK signaling cascades by alpha1-integrins during colon cancer cell invasion. Int J Oncol (2007) 1.16
TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis. Blood (2014) 1.13
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst (2011) 1.08
Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene (2011) 1.06
Mesenchymal gene program-expressing ovarian cancer spheroids exhibit enhanced mesothelial clearance. J Clin Invest (2014) 1.05
Generation and phenotypic characterization of new human ovarian cancer cell lines with the identification of antigens potentially recognizable by HLA-restricted cytotoxic T cells. Int J Cancer (1997) 1.02
Axl phosphorylates Elmo scaffold proteins to promote Rac activation and cell invasion. Mol Cell Biol (2014) 1.02
p130Cas: a key signalling node in health and disease. Cell Signal (2012) 1.01
A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. Oncotarget (2015) 1.00
Axl as a mediator of cellular growth and survival. Oncotarget (2014) 0.99
Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clin Cancer Res (2015) 0.95
Axl receptor activation mediates laminar shear stress anti-apoptotic effects in human endothelial cells. Cardiovasc Res (2006) 0.94
Development and validation of an ELISA method for detection of growth arrest specific 6 (GAS6) protein in human plasma. J Immunoassay Immunochem (2008) 0.93
Discrete molecular classes of ovarian cancer suggestive of unique mechanisms of transformation and metastases. Clin Cancer Res (2013) 0.93
Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells. Cancer Biol Ther (2014) 0.81
A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. Oncotarget (2015) 1.00
Pleiotropic modes of action in tumor cells of RNASET2, an evolutionary highly conserved extracellular RNase. Oncotarget (2015) 0.76
p130Cas/BCAR1 scaffold protein in tissue homeostasis and pathogenesis. Gene (2015) 0.75